Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

about

Biomarkers in hypertension and their relationship with myocardial target-organ damage.

P2860

Q38258970-EF22E317-1284-4C56-B9C0-629E24A898FD

P2860

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

Item

http://www.wikidata.org/entity/Q48548331

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@en

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@nl

type

Item

label

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@en

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@nl

prefLabel

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@en

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@nl

P1476

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

@en

P2093

Björn Dahlöf

http://www.w3.org/2001/XMLSchema#string

Christian Hall

http://www.w3.org/2001/XMLSchema#string

Erik Rydberg

http://www.w3.org/2001/XMLSchema#string

Ronnie Willenheimer

http://www.w3.org/2001/XMLSchema#string

Stefan Jovinge

http://www.w3.org/2001/XMLSchema#string

P2860

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Diagnostic ability of B-type natriuretic peptide and impedance cardiography: testing to identify left ventricular dysfunction in hypertensive patients.

Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction.

Clinical applications of B-type natriuretic peptide (BNP) testing.

Biology of the natriuretic peptides.

Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney.

N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis.

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

P304

196-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/08037050903083298

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anders Grubb

Olav Wendelboe Nielsen

Martin Magnusson

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19562575

http://www.w3.org/2001/XMLSchema#string

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

about

P2860

P2860

Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698